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AbstrACt
Objective To examine the relationship between 
glycated haemoglobin A1c (HbA1c) levels and the risk of 
cardiovascular outcomes and all-cause mortality based 
on data from observational studies and to determine the 
optimal levels of HbA1c for preventing cardiovascular 
events and/or mortality in diabetic and non-diabetic 
populations.
review methods We systematically searched Medline, 
Embase, the Cochrane Central Register of Controlled 
Trials, the Cochrane Database of Systematic Reviews and 
Web of Science databases, from inception to July 2016, 
for observational studies addressing the association 
of HbA1c levels with mortality and cardiovascular 
outcomes. Random effects models were used to compute 
pooled estimates of HR and respective 95% CI for all-
cause mortality, cardiovascular mortality and risk of 
cardiovascular events, separately for people with and 
without diabetes.
results Seventy-four published studies were included 
in the systematic review, but only 46 studies could be 
incorporated in the meta-analysis. In both diabetic and non-
diabetic populations, there was an increase in the risk of 
all-cause mortality when HbA1c levels were over 8.0% and 
6.0%, respectively. The highest all-cause mortality in people 
with diabetes was HbA1c above 9.0% (HR=1.69; 95% CI 
1.09 to 2.66) and in those without diabetes was HbA1c 
above 6.0% (HR=1.74; 95% CI 1.38 to 2.20). However, both 
diabetic and non-diabetic populations with lower HbA1c 
levels (below 6.0% HR=1.57; 95% CI 1.14 to 2.17 and below 
5.0% HR=1.19; 95% CI 1.04 to 1.36, respectively) had higher 
all-cause mortality. Similar pooled estimates were found 
when cardiovascular mortality was the outcome variable.
Conclusion HbA1c is a reliable risk factor of all-cause 
and cardiovascular mortality in both diabetics and non-
diabetics. Our findings establish optimal HbA1c levels, for 
the lowest all-cause and cardiovascular mortality, ranging 
from 6.0% to 8.0% in people with diabetes and from 5.0% 
to 6.0% in those without diabetes.
IntrOduCtIOn
Cardiovascular diseases (CVD) are the first 
cause of mortality in the world, representing 
31% of all global deaths. In 2012, 17.5 million 
people died by CVD according to WHO.1 
Prevention of CVD through the control of 
risk factors is a priority in most developed 
countries.2
Glycated haemoglobin A1c (HbA1c) level 
is an indicator of the average blood glucose 
concentrations over the preceding 2 to 3 months 
that is recommended by the American Diabetes 
Association (ADA)3 and the WHO4 for the diag-
nosis of diabetes. This indicator has exhibited 
strengths and limitations of this study
 ► Previous meta-analyses have reported pooled 
estimates of the increase in mortality risk by each 
1% increase in glycated haemoglobin A1c (HbA1c); 
thus, their estimates are based on the assumption of 
a linear relationship between these variables, which 
data from the studies included in this review did not 
show.
 ► This study provides pooled estimates of changes 
in mortality risk by HbA1c level categories, and 
therefore, did not presuppose any functional 
statistical relationship between the involved 
variables.
 ► Our findings establish that, to diminish cardiovascular 
and all-cause mortality, optimal HbA1c levels range 
from 5.0% to 6.0% in people without diabetes and 
from 6.0% to 8.0% in people with diabetes.
 ► Publication bias cannot be disregarded because, 
although 74 studies met the inclusion criteria, only 
46 were considered for our pooled estimates, since 
the other 28 reported their results using HbA1c 
levels not comparable to those of the studies 
included in the meta-analysis.
 ► To assess the magnitude of publication bias, we 
calculated the number of unpublished or unrecovered 
null studies that would have been published to 
make the effect not statistically significant using the 
Rosenthal fail-safe N method.
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more accuracy for the diagnosis of diabetes retinopathy 
than fasting plasma glucose (FPG),5 an early diabetes-re-
lated complication that is considered a good criterion for 
comparing the diagnostic accuracy of diabetes biomarkers.6 
HbA1c levels have also been proved to be useful in algo-
rithms for calculating cardiovascular risk, along with age, 
gender, smoking status, blood pressure and cholesterol,7–9 
and therefore may be a relevant biomarker to be considered 
in CVD prevention strategies.10 11
An increased mortality at both high and low HbA1c 
levels has been reported in a meta-analysis of obser-
vational studies including type 2 diabetes patients.12 
Another meta-analysis, but in subjects without known 
diabetes, reported a non-linear association between 
HbA1c and mortality from all causes, CVD and cancer, 
providing a relatively flat curve dose–response for 
HbA1c levels around 5.7% and which rose steeply there-
after.13 Thus, although the existence of a ‘security zone’ 
of HbA1c levels for diabetes management has been 
suggested, the existence of optimum clinical HbA1c 
targets is a controversial issue in subjects with and 
without diabetes.
The aims of this systematic review and meta-analysis were 
to: (1) estimate the relationship between HbA1c levels 
and the risk of cardiovascular outcomes and all-cause 
mortality based on data from observational studies and 
(2) analyse the range of HbA1c that is the most likely to 
prevent CVD and/or mortality in populations with and 
without diabetes.
Methods
This study was reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses14 (figure 1) and the Meta-analysis of Observational 
studies in Epidemiology15 statements and followed the 
recommendations of the Cochrane Collaboration Hand-
book.16 This systematic review and meta-analysis was 
registered through Prospective Register of systematic 
reviews (Registration number: CRD42015032552) and its 
protocol has been published elsewhere.17
Search strategy
We systematically searched Medline (via PubMed), 
Embase, the Cochrane Central Register of Controlled 
Trials, the Cochrane Database of Systematic Reviews and 
Web of Science databases from their inception until July 
2016. Articles addressing the association of HbA1c levels 
with all-cause and cardiovascular mortality and/or any 
cardiovascular outcomes and based on data from obser-
vational studies were eligible. The search expressions are 
presented in the online supplementary table A. The liter-
ature search was complemented by reviewing citations of 
the articles considered eligible for the systematic review.
Study selection
The criteria for excluding studies were as follows: (1) 
reports not written in English, Portuguese or Spanish, 
(2) studies without a longitudinal design, (3) studies not 
reporting risk of mortality or cardiovascular outcomes, 
such as myocardial infarction, stroke, major adverse 
Figure 1 Literature search Preferred Reporting Items for Systematic Reviews and Meta-Analyses consort diagram. HbA1c, 
glycated haemoglobin A1c; WOS, Web of Science.
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cardiovascular events, coronary heart disease and heart 
failure, (4) studies not using Cox proportional hazards 
models to measure cardiovascular outcomes or mortality, 
(5) studies including individuals aged below 18 years old, 
(6) non-eligible publication types, such as review arti-
cles, editorials, comments, guidelines or case reports, (7) 
studies not providing data to compare different levels of 
HbA1c and (8) duplicate reports of the same study.
When more than one study provided data referring to 
the same sample, we considered the one presenting the 
results with more detail or providing data for the largest 
sample size. However, data regarding sample character-
istics could be extracted from the multiple reports to 
obtain the most complete information.
The literature search was performed independently by 
two reviewers (ICR and CAB), and disagreements were 
solved by consensus or involving a third researcher (BP).
Data extraction and quality assessment
The following data were extracted from the original 
reports:  (1) year of publication,  (2) country, (3) study 
design, (4) study/project designation and period of data 
collection, (5) length of follow-up, (6) sample charac-
teristics (sample size and age distribution), (7) type of 
population (with diabetes or without diabetes, including 
subjects without known diabetes), (8) diabetes diagnosis 
criteria, (9) methods used in HbA1c assay, (10) level of 
HbA1c used as the reference and (11) number of cardio-
vascular events and/or deaths.
The Quality in Prognosis Studies (QUIPS) tool18 was 
used to evaluate the risk of bias in six domains: study 
participation (sampling bias), study attrition (attrition 
bias), prognostic factor measurement, outcome measure-
ment (ascertainment bias), confounding measurement 
and accounting and analysis and reporting. Studies were 
considered to have a low, moderate or high risk of bias, if 
they satisfied five to six, three to four or one to two of the 
six domains, respectively.
Data extraction and quality assessment were inde-
pendently performed by two reviewers (ICR and CAB) 
and inconsistencies were solved by consensus or involving 
a third researcher (BP).
Statistical analysis and data synthesis
The DerSimonian and Laird method19 was used to 
compute pooled estimates of HR and respective 95% 
95% CI for all-cause mortality, cardiovascular mortality 
and risk of cardiovascular events, separately for people 
with diabetes and without diabetes. The heterogeneity 
of the results across studies was evaluated using the I2 
statistic. I2 values of <25%, 25%–50% and >50% usually 
correspond to small, medium and large heterogeneity, 
respectively.20 The corresponding p values were also 
considered. At least four observations providing HR esti-
mates were required to conduct meta-analysis.
When studies presented several statistical risk-adjust-
ment models, we considered those that included the 
largest number of additional covariates. A pooled HR 
estimate for each HbA1c level was calculated with the 
DerSimonian and Laird method using the specific HR 
reported in the studies. Furthermore, in the meta-anal-
yses of cardiovascular events’ incidence, pooled HR 
estimates were computed taking into account all of the 
possible events (myocardial infarction, stroke, major 
adverse cardiovascular events, coronary heart disease and 
heart failure). For each HR estimate, the natural log HR 
(lnHR) was calculated by converting it to the natural log 
scale.
Additionally, for all-cause mortality, HR estimates for 
each HbA1c category from all studies were converted 
onto a common scale using HbA1c <6.0% as reference 
category for population with diabetes and HbA1c <5.0% 
for those without diabetes. HR estimate was reciprocated 
from risk or protective factor to reference value.21
Sensitivity analyses were conducted to assess the robust-
ness of the summary estimates and to detect if any particular 
study accounted for a large proportion of heterogeneity. 
In addition, random-effects meta-regression was used to 
evaluate whether results differed according to the mean 
age of the participants and the length of follow-up,22 as 
these could be considered major sources of heteroge-
neity. Subgroup analyses were performed based on the 
risk of bias assessed by the QUIPS tool (low, moderate or 
high risk of bias).
Finally, publication bias was evaluated through visual 
inspection of the funnel plots, as well as by using the 
method proposed by Egger.23 Also, Rosenthal's fail-safe 
N method was used to determine the number of unpub-
lished or unretrieved null studies that would be needed 
to increase the p value above 0.05 (to make the effect not 
statistically significant).24
Statistical analyses were performed using Stata/SE soft-
ware V.14.
Patient involvement
Neither patients were involved in the election of the 
research question or the outcome measures nor  they were 
involved in the design or implementation of the study. 
No patients were asked regarding the interpretation or 
writing up of results. There are no plans to disseminate 
the results of the research to study participants or the 
patient community.
results
Systematic review
We identified 74 studies (see figure 1 and both a full list 
of references of included studies in the online supple-
mentary references and online supplementary table B) 
quantifying the HR for the association between HbA1c 
levels and the risk of all-cause mortality, cardiovas-
cular mortality or risk of cardiovascular events, which 
were conducted in 20 countries: three from the Amer-
icas, seven from Asia, nine from Europe and one from 
Oceania.
The reports were published between 2005 and 2016 
and provided data collected between 1979 and 2013. The 
follow-up duration varied across studies, from 3 months 
to 18 years.
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Regarding the characteristics of the population evalu-
ated in the studies, 37 were performed in medical centres, 
25 were community based, nine used national databases, 
two used hospital databases and one was conducted in an 
elderly institution. Included subjects were aged between 
25 and 90 years, with sample sizes ranging from 78 to 
548 808 subjects. The studies included populations with 
diabetes, without diabetes or both (in general population, 
in patients with disease and in patients with renal disease). 
The data extracted from the included studies were 
adjusted for several covariates (see online supplementary 
table C).
The diagnosis criteria guidelines used to ascertain the 
diagnosis of diabetes mellitus were specified in 31 studies 
(ADA, International Statistical Classification of Diseases 
and Related Health Problems, WHO, Read Codes or 
Experts Committee). Only 18 studies used certified 
national glycohaemoglobin standardisation programme 
methods for the assessment of HbA1c level.
Study quality
As assessed by the QUIPS tool (see online supplemen-
tary table D), 39% of the studies obtained a total score 
corresponding to a low risk of bias, 57% moderate 
and only 4% had a high risk of bias. The study attri-
tion domain showed a high risk of bias in most studies 
(72%). Conversely, 77% of the studies showed a low risk 
of bias in the statistical analysis and reporting domain, 
and no study scored a high risk of bias in study partic-
ipation.
Meta-analyses
To more clearly display the pooled HR estimates of 
all-cause mortality, cardiovascular mortality and risk of 
cardiovascular events, we have provided figures including 
the pooled HR estimates, their 95% CI and the I2 hetero-
geneity statistic for each HbA1c level, using the different 
reference values of this biochemical parameter provided 
by the included studies (figures 2–5). The corresponding 
forest plots are available as online supplementary figures 
A–F).
All-cause mortality in diabetic population
Regardless of the reference value, the pooled HR 
increased significantly (p<0.05) for HbA1c levels above 
9.0% (figure 2A–D) and for HbA1c ranging from 8.0% 
to 9.0% (figure 2B, C and D). For levels of HbA1 below 
6.0%, the pooled HR estimates were also significantly 
higher (p<0.01) as compared with the reference values 
(supplementary figure G and figure 2B and D). There was 
substantial heterogeneity between the studies included, 
except for HbA1c levels below 6.0% (I2=0.0%, figure 2B) 
and HbA1c ranging from 8.0% to 9.0% (I2=25.3%, 
figure 2C).
When pooled HR was calculated converting 
HbA1c <6.0% as reference level, an increase of risk was 
shown at HbA1c level >9.0% (p<0.001). Conversely, 
HbA1c levels 6.0% to 7.0% and 7.0% to 8.0% were 
presented as protective factor (p<0.001).
All-cause mortality in non-diabetic population (
Overall, levels of HbA1c above 6.0% were significantly 
(p<0.001) associated with higher pooled HR estimates 
(figure 3A–C). Also, for levels of HbA1 below 5.0%, the 
pooled HR estimates were significantly higher (p<0.01) 
as compared with the reference values (figure 3C). There 
was no heterogeneity between the studies included.
When pooled HR was calculated converting 
HbA1c <5.0% as reference level an increase of risk was 
shown at HbA1c level >6.0% (p<0.05) (see online supple-
mentary figure G).
Cardiovascular mortality and risk of events in diabetic population
HbA1c levels above 7.0% were associated (p<0.05) 
with a higher pooled HR for cardiovascular mortality 
(figure 4A.1). Overall, pooled estimates of HR for HbA1c 
levels above 6.0% were not significantly associated with 
a higher risk of cardiovascular events (figure 4B.1 and 
4B2). There was substantial heterogeneity between the 
studies included.
Cardiovascular mortality and risk of events in non-
diabetic population
Overall, HbA1c levels higher than 6.0% were significantly 
associated with higher pooled HR estimates for cardiovas-
cular mortality (figure 5A.1 and 5A.3). This also occurs 
when the HbA1c level was above 6.5% (figure 5A.2). 
Additionally, when HbA1c levels were above 5.0% and 
were compared with lower HbA1c levels (figure 5A.1), the 
pooled HR estimates increased (p<0.01). As compared 
with levels of HbA1c between 5.0% and 6.0%, levels below 
5.0% were not significantly associated with higher pooled 
HR estimates for both risk of cardiovascular events and 
cardiovascular mortality (figure 5A.3 and 5B.1). There 
was only substantial heterogeneity for Hba1c levels above 
6.0% (figure 5A.1) and and HbA1c ranging from 5.5% to 
6.5% (figure 5A.2).
Sensitivity analysis, meta-regression subgroup analysis and 
publication bias
When the impact of individual studies was examined 
by removing studies from the analyses one by one, the 
pooled HR for all-cause mortality in diabetics increased 
only when removing the Ricks et al study. We also observed 
that there were seven studies for all-cause mortality 
in diabetic population and one for all-cause mortality 
in non-diabetic population, for which heterogeneity 
decreased when they were removed.
The metaregression model showed that the length 
of follow-up was associated with heterogeneity across 
studies of all-cause mortality in diabetics at HbA1c levels 
above 9.0% as compared with reference level below 
6.0% (p=0.036) and across studies of all-cause mortality 
in those without diabetes at HbA1c levels below 5.0% 
as compared with HbA1c ranging from 5.0% to 5.9% 
(p=0.027). The mean age of the participants was associ-
ated with heterogeneity across studies in the meta-analysis 
of cardiovascular mortality in non-diabetic population at 
HbA1c levels above 6.0% using HbA1c below 5.0% as the 
reference level (p=0.042).
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Subgroup analyses based on the risk of bias assessed by 
the QUIPS tool showed a decrease in some pooled HR 
estimates when the analysis was performed in studies with 
low risk of bias (see online supplementary table E).
Egger’s test showed potential publication bias for 
all-cause mortality in diabetic population at HbA1c 
ranging from 6.0% to 7.0%, using HbA1c levels below 
6.0% as the reference (p=0.006; Fail-safe N test=0) and 
Figure 2 Pooled HRs for all-cause mortality in diabetic population, according to HbA1c levels. HbA1c, glycated haemoglobin 
A1c.
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at HbA1c below 6.0% using HbA1c ranging from 7.0% to 
8.0% as the reference level (p=0.046; Fail-safe N test=197). 
For cardiovascular mortality in non-diabetic population, 
potential publication bias was detected at HbA1c levels 
above 6.5% when HbA1c below 5.5% was the reference 
(p=0.029; Fail-safe N test=14) and at HbA1c below 5.0% 
when HbA1c ranging from 5.0% to 5.9% was the refer-
ence level (p=0.048; Fail-safe N test=1).
discussion
This systematic review and meta-analysis provides an over-
view of the evidence supporting that HbA1c is a risk factor 
for mortality and cardiovascular outcomes. Our data 
confirm the association between chronic hyperglycaemia 
and cardiovascular complications and also highlights the 
importance of considering hypoglycaemia levels in this 
association. Furthermore, this meta-analysis establishes 
the optimal HbA1c associated with the lowest all-cause 
and cardiovascular mortality ranging from 6.0% to 8.0% 
in diabetic population and 5.0% and 6.0% in non-dia-
betic population.
All-cause mortality
Previous systematic reviews and meta-analyses have 
analysed the all-cause mortality associated with several 
HbA1c levels using the HR per 1% increase in HbA1c 
or the relative risk (RR) per 1% increase in HbA1c. 
These studies have reported an increase for all-cause 
mortality in patients with diabetes with HbA1c levels 
around 7.5%12 25 and in subjects without known 
diabetes,13 with HbA1c levels around 5.7%. Our find-
ings show an increase in all-cause mortality when HbA1c 
Figure 3 Pooled HRs for all-cause mortality in non-diabetic population, according to HbA1c levels. HbA1c, glycated 
haemoglobin A1c.
group.bmj.com on April 3, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Cavero-Redondo I, et al. BMJ Open 2017;7:e015949. doi:10.1136/bmjopen-2017-015949
Open Access
levels are above 8.0%, but also below 6.0%, for people 
with known diabetes and above 6.0% or below 5.0% for 
clinical non-diabetic patients. Thus, our data reinforce 
previous findings26 and support the clinical importance 
of preventing hypoglycaemia in the diabetic population 
and in those without a diagnosis of diabetes, in such a 
way that it suggests that the optimal range for HbA1c 
might be established from 6.0% to 8.0% in patients with 
diabetes and from 5.0% to 6.0% in non-diabetic patients. 
Although previous studies have reported an increase in 
mortality risk by each 1% increase in HbA1c, their esti-
mates are based on the assumption of a linear relationship 
between these variables, which the data from studies 
included in this review did not show. Thus, providing 
estimates of changes in mortality risk by HbA1c level 
categories did not presuppose any functional statistical 
relationship between the involved variables.
Cardiovascular mortality
A previous meta-analysis13 in a non-diabetic population 
estimated an increase of 5% in cardiovascular mortality 
per 1% increase in HbA1c levels, though this relation-
ship was curvilinear and the dose–response curve was 
flat for levels of HbA1c below 5.7%. However, despite its 
Figure 4 Pooled HRs for cardiovascular mortality and risk of cardiovascular events in diabetic population, according to HbA1c 
levels. HbA1c, glycated haemoglobin A1c.
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Figure 5 Pooled HRs for cardiovascular mortality and risk of cardiovascular events in non-diabetic population, according to 
HbA1c levels. HbA1c, glycated haemoglobin A1c.
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clinical importance, there is a lack of summary estimates 
regarding the level of HbA1c from which cardiovascular 
mortality is significantly increased. Our data support that 
cardiovascular mortality is significantly increased when 
HbA1c levels are above 8.0% in the population with 
diabetes and above 6.0% in those without. Thus, our 
findings confirm the previous results in the population 
without diabetes, provide estimates regarding the levels 
of HbA1c from which cardiovascular mortality increases 
significantly and reinforce the idea that HbA1c may be 
included in algorithms to calculate cardiovascular risk in 
clinical settings.7–9
Cardiovascular events’ incidence
To summarise the increase or decrease of risk of cardio-
vascular events associated with HbA1c levels from data of 
individual follow-up studies is a complex task because of 
the variety of health conditions susceptible to be included 
in this clinical entity. The only meta-analysis that has 
addressed this issue in patients with type 2 diabetes esti-
mated that each 1% increase in HbA1c was associated 
with 17% of cardiovascular events’ incidence.25 However, 
these findings are affected by the length of follow-up 
because relative risk only takes into account the occur-
rence of the event at the end of follow-up and there was 
a wide range in the length of follow-up in the included 
studies. Our data are in accordance with these estimates 
though only for people without known diabetes, in which 
20% of risk of cardiovascular events in HbA1c levels above 
6.0% was observed.
Heterogeneity assessment
Regarding the clinical variability of the samples of the 
studies included in this meta-analysis, the age of the 
subjects could be related with the outcome variables 
observed. It seems judicious to assume that studies in 
which an elderly population was included, mortality rates 
would be higher.27 However, our meta-regression analysis 
did not find any relationship between the mean age of 
participants and the observed variables, except for one 
subgroup analysis for cardiovascular mortality in those 
without diabetes. This is the only subgroup analysis that 
pooled subjects with the mean age of 38 years and the 
mean age above 51 years. Age is one of the primary risk 
factors for CVD and is associated with worst likelihood 
values in modifiable risk factors and risk of mortality.28 
Otherwise, variability in the follow-up is considered 
an essential indicator of quality.29 We did not observe 
a relationship between the length of follow-up and the 
outcomes observed, except for two subgroup analyses 
which included studies involving elderly individuals and 
patients with a history of heart failure or kidney disease. 
The HR for all-cause mortality in these populations was 
closely related to the duration of the study, since life 
expectancy in these samples is substantially shorter.
The heterogeneity across subgroup analysis was 
decreased only by the exclusion of seven studies. Different 
sources could cause the described heterogeneity among 
studies: (1) The target population involved subjects from 
the general population to patients with cardiovascular 
or renal disease, but previous evidence including equal 
target populations obtained similar results;30 (2) Subjects 
came from different countries, there is evidence of differ-
ences in the prevalence of diabetes, CVD and mortality 
across countries,31–33 with East and Southeast Asia 
(excluding Japan) showing higher prevalences. Only five 
studies included in the meta-analyses were developed in 
these regions and only one lead to an increase in hetero-
geneity; (3)The criteria for the diagnosis of diabetes have 
changed over time.34 During the 1980s and part of the 
1990s, the diabetes diagnosis criteria was a fasting plasma 
glucose (FPG) above 7.8 mmol/L,35 this was lowered to 
7.0 mmol/L36 in 1997. Finally, the HbA1c level above 
6.5% was included as a criterion for diabetes diagnosis 
in 2009.37–39 As the studies were conducted between 1979 
and 2013, the progressive change in the diabetes diag-
nosis criteria could produce misclassification of people 
with diabetes or without diabetes; (4) Including retro-
spective studies could affect the accuracy of the data 
collected for exposures.40
The limitations of this study are common to other 
meta-analyses: selection bias, potential ecological fallacy 
and reporting bias. There was evidence for significant 
publication bias in 4 of the 37 meta-analyses included; 
it is possible that underpowered studies are less likely 
to be published. Among the reasons for this publication 
bias, we can highlight that due to the wide segmen-
tation of data from the studies included in this review, 
some meta-analyses included a small number of studies, 
thus publication bias is likely. Furthermore, from the 74 
retrieved studies, only 46 were included in the pooled 
estimates, the other 28 studies reported their results using 
HbA1c categories not comparable with the included 
studies; thus, publication bias cannot be disregarded, 
although these excluded studies provided HR estimates 
similar to the pooled estimates obtained. Moreover, since 
26 studies were excluded because they provided results 
using a continuous approach, and they presented an HR 
estimate corresponding to an increase of 1 SD or 1% in 
HbA1c level, this could contribute to publication bias. 
Furthermore, using categories in the included studies 
may have contributed to publication bias and bias in HR 
estimates because categorising continuous variables can 
increase the type 1 error rate.41 To assess the magnitude 
of this bias, we determined the number of unpublished 
or unrecovered null studies that would have been 
published to make the effect not statistically significant 
using the Rosenthal fail-safe N method.24 Finally, of the 
six excluded studies reporting relative risk or OR esti-
mates, only one study reported an assessment of mortality 
risk including OR as a measure of effect and using cate-
gories of HbA1c comparable to those of the other studies 
(see online supplementary table F). Therefore, although 
the exclusion of these studies might bias our pooled esti-
mates, these studies provided risk estimates similar to the 
pooled estimates obtained. Due to the diversity of the 
HbA1c reference values used in the studies, we had to 
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group them into categories for comparing the pooled 
HR estimates for cardiovascular outcomes and all-cause 
mortality. Despite our efforts to use a comprehensive 
approach, we should also consider that the meta-anal-
yses were not conducted with the raw data provided by 
the authors of each study, thus the calculation of HR and 
corresponding 95% CI from the published data could 
bias our pooled estimates. Unlike other meta-analyses 
of observational studies, we have only included pooled 
estimates of HR, an epidemiological association measure 
that takes into account the occurrence of the event at 
the end of follow-up, as OR and RR, and when the event 
occurs during the follow-up period. Lastly, since many 
confounders were controlled for in most studies when 
computing HR, the external validity of our estimates 
of all-cause mortality, cardiovascular mortality and risk 
of cardiovascular events, in both diabetic and non-dia-
betic populations, could be reinforced.
COnClusIOn
HbA1c is a reliable risk factor for all-cause mortality 
and cardiovascular mortality in both non-diabetic and 
diabetic populations. Although the appropriate use of 
our meta-analysis results should be understood in each 
particular clinical context, our data suggest that clini-
cians should consider the level of HbA1c when they 
assess the risk of cardiovascular and all-cause mortality of 
each individual patient, and provide an optimal range of 
HbA1c levels that is associated with lower mortality and 
cardiovascular events’ incidence. Particularly, our data 
suggest that clinicians should advise their patients with 
diabetes to maintain their HbA1c levels in the range of 
6.0% to 8.0% and also that the target limits for HbA1c 
in individuals without diabetes should be in the range 
of 5.0% to 6.0%. Notwithstanding, more research specif-
ically addressed to evaluating the appropriateness of 
including this biomarker as a routine analytical param-
eter for the assessment of cardiovascular risk is needed.
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